SC-291

N/A

Report date: 2024/12/05 13:54:36

Base Information

Drug NameSC-291

Drug Alias NameSC-291SC291

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[10]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSana Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesSana Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[10]

Inactive IndicationsN/A

Other Information

ATC CodeN/A